Verona Pharma (VRNA) Stock Forecast, Price Target & Predictions
VRNA Stock Forecast
Verona Pharma stock forecast is as follows: an average price target of $39.50 (represents a -6.00% downside from VRNA’s last price of $42.02) and a rating consensus of 'Buy', based on 8 wall street analysts offering a 1-year stock forecast.
VRNA Price Target
The average price target for Verona Pharma (VRNA) is $39.50 based on 1-year price targets from 8 Wall Street analysts in the past 3 months, with a price target range of $42.00 to $37.00. This represents a potential -6.00% downside from VRNA's last price of $42.02.
VRNA Analyst Ratings
According to 8 Wall Street analysts, Verona Pharma's rating consensus is 'Buy'. The analyst rating breakdown for VRNA stock is 0 'Strong Buy' (0.00%), 8 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Verona Pharma Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Nov 05, 2024 | Raghuram Selvaraju | H.C. Wainwright | $42.00 | $38.39 | 9.40% | -0.05% |
| Jul 22, 2024 | Edward Nash | Canaccord Genuity | $37.00 | $22.95 | 61.22% | -11.95% |
| Jun 27, 2024 | Raghuram Selvaraju | H.C. Wainwright | $36.00 | $14.69 | 145.06% | -14.33% |
| May 28, 2024 | Andrew Tsai | Jefferies | $38.00 | $12.50 | 204.00% | -9.57% |
| Apr 16, 2024 | Yasmeen Rahimi | Piper Sandler | $36.00 | $15.80 | 127.85% | -14.33% |
| Dec 21, 2022 | H.C. Wainwright | $32.00 | $18.59 | 72.14% | -23.85% | |
| Dec 20, 2022 | Andreas Argyrides | Wedbush | $30.00 | $18.05 | 66.20% | -28.61% |
| Dec 20, 2022 | Truist Financial | $28.00 | $18.13 | 54.48% | -33.37% | |
| Dec 20, 2022 | BTIG | $26.00 | $18.14 | 43.29% | -38.12% | |
| Aug 30, 2022 | Edward Nash Nash | Canaccord Genuity | $27.00 | $10.25 | 163.41% | -35.74% |
| Aug 30, 2022 | Raghuram Selvaraju Selvaraju | H.C. Wainwright | $30.00 | $9.90 | 203.03% | -28.61% |
| Aug 30, 2022 | Liana Moussatos Moussatos | Wedbush | $23.00 | $9.90 | 132.32% | -45.26% |
The latest Verona Pharma stock forecast, released on Nov 05, 2024 by Raghuram Selvaraju from H.C. Wainwright, set a price target of $42.00, which represents a 9.40% increase from the stock price at the time of the forecast ($38.39), and a -0.05% decrease from VRNA last price ($42.02).
Verona Pharma Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 5 |
| Avg Price Target | - | $42.00 | $37.80 |
| Last Closing Price | $42.02 | $42.02 | $42.02 |
| Upside/Downside | -100.00% | -0.05% | -10.04% |
In the current month, the average price target of Verona Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Verona Pharma's last price of $42.02. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Oct 03, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Oct 03, 2024 | Wells Fargo | Overweight | Initialise | |
| Sep 12, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Aug 14, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 22, 2024 | Canaccord Genuity | Buy | Buy | Hold |
| Jun 27, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jun 27, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| May 13, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Apr 16, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Dec 20, 2022 | BTIG | Buy | Buy | Hold |
| Aug 29, 2022 | Raymond James | Buy | Buy | Hold |
| Jun 22, 2022 | Truist Financial | Buy | Buy | Hold |
| Apr 26, 2022 | Zacks Investment Research | Buy | Upgrade |
Verona Pharma's last stock rating was published by Piper Sandler on Oct 03, 2024. The company gave VRNA a "Overweight" rating, the same as its previous rate.
Verona Pharma Financial Forecast
Verona Pharma Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | $458.00K | - | $40.00M |
| Avg Forecast | $79.01M | $49.99M | $43.47M | $36.22M | $43.90M | $38.37M | $29.86M | $20.89M | $13.15M | $1.51M | $263.34K | $4.08M | $4.52M | $4.63M |
| High Forecast | $109.33M | $69.17M | $60.15M | $50.12M | $60.74M | $53.10M | $41.32M | $27.15M | $15.52M | $1.53M | $364.39K | $5.64M | $4.52M | $4.63M |
| Low Forecast | $59.77M | $37.82M | $32.88M | $27.40M | $33.21M | $29.03M | $22.59M | $17.20M | $11.79M | $1.50M | $199.21K | $3.08M | $4.52M | $4.63M |
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 3 | 3 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.11% | - | 8.65% |
Verona Pharma's average Quarter revenue forecast for Jun 24 based on 4 analysts is $263.34K, with a low forecast of $199.21K, and a high forecast of $364.39K. VRNA's average Quarter revenue forecast represents a -42.50% decrease compared to the company's last Quarter revenue of $458.00K (Dec 22).
Verona Pharma EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 3 | 3 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | $-12.24M | $-12.06M | $11.43M |
| Avg Forecast | $-15.80M | $-10.00M | $-8.69M | $-7.24M | $-8.78M | $-7.67M | $-5.97M | $-4.18M | $-2.63M | $-302.52K | $-52.67K | $-815.19K | $-903.90K | $-925.22K |
| High Forecast | $-11.95M | $-7.56M | $-6.58M | $-5.48M | $-6.64M | $-5.81M | $-4.52M | $-3.44M | $-2.36M | $-299.35K | $-39.84K | $-616.68K | $-903.90K | $-925.22K |
| Low Forecast | $-21.87M | $-13.83M | $-12.03M | $-10.02M | $-12.15M | $-10.62M | $-8.26M | $-5.43M | $-3.10M | $-305.70K | $-72.88K | $-1.13M | $-903.90K | $-925.22K |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 15.01% | 13.35% | -12.35% |
3 analysts predict VRNA's average Quarter EBITDA for Sep 22 to be $-903.90K, with a high of $-903.90K and a low of $-903.90K. This is -107.91% lower than Verona Pharma's previous annual EBITDA (Sep 21) of $11.43M.
Verona Pharma Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 3 | 3 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | $-10.45M | $-15.65M | $11.05M |
| Avg Forecast | $2.57M | - | $-642.34K | $-1.28M | $-2.09M | $-2.25M | $-2.73M | $-2.89M | $-3.34M | $-4.14M | $-2.90M | $374.35K | $-878.88K | $-11.53M |
| High Forecast | $3.85M | - | $-439.00K | $-878.00K | $-1.43M | $-1.54M | $-1.87M | $-2.41M | $-2.97M | $-2.83M | $-1.98M | $561.11K | $-878.88K | $-11.53M |
| Low Forecast | $1.76M | - | $-962.80K | $-1.93M | $-3.13M | $-3.37M | $-4.09M | $-3.21M | $-3.71M | $-6.21M | $-4.34M | $255.84K | $-878.88K | $-11.53M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | -27.92% | 17.80% | -0.96% |
Verona Pharma's average Quarter net income forecast for Sep 22 is $-878.88K, with a range of $-878.88K to $-878.88K. VRNA's average Quarter net income forecast represents a -107.95% decrease compared to the company's last Quarter net income of $11.05M (Sep 21).
Verona Pharma SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 3 | 3 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | $8.32M | $5.29M | $10.88M |
| Avg Forecast | $61.42B | $38.86B | $33.79B | $28.16B | $34.12B | $29.83B | $23.21B | $16.24B | $10.22B | $1.18B | $204.70M | $3.17B | $3.51B | $3.60B |
| High Forecast | $84.99B | $53.77B | $46.76B | $38.96B | $47.22B | $41.27B | $32.12B | $21.11B | $12.06B | $1.19B | $283.26M | $4.38B | $3.51B | $3.60B |
| Low Forecast | $46.46B | $29.40B | $25.56B | $21.30B | $25.81B | $22.56B | $17.56B | $13.37B | $9.16B | $1.16B | $154.86M | $2.40B | $3.51B | $3.60B |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | 0.00% | 0.00% | 0.00% |
Verona Pharma's average Quarter SG&A projection for Jun 24 is $204.70M, based on 4 Wall Street analysts, with a range of $154.86M to $283.26M. The forecast indicates a 2359.49% rise compared to VRNA last annual SG&A of $8.32M (Dec 22).
Verona Pharma EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Dec 22 | Sep 22 | Sep 21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 4 | 5 | 4 | 4 | 3 | 3 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | $-0.18 | $-0.23 | $0.16 |
| Avg Forecast | $0.03 | - | $-0.01 | $-0.02 | $-0.03 | $-0.03 | $-0.03 | $-0.04 | $-0.04 | $-0.05 | $-0.04 | - | $-0.01 | $-0.14 |
| High Forecast | $0.05 | - | $-0.01 | $-0.01 | $-0.02 | $-0.02 | $-0.02 | $-0.03 | $-0.04 | $-0.03 | $-0.02 | $0.01 | $-0.01 | $-0.14 |
| Low Forecast | $0.02 | - | $-0.01 | $-0.02 | $-0.04 | $-0.04 | $-0.05 | $-0.04 | $-0.05 | $-0.08 | $-0.05 | - | $-0.01 | $-0.14 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | -39.18% | 21.20% | -1.12% |
According to 3 Wall Street analysts, Verona Pharma's projected average Quarter EPS for Sep 22 is $-0.01, with a low estimate of $-0.01 and a high estimate of $-0.01. This represents a -106.78% decrease compared to VRNA previous annual EPS of $0.16 (Sep 21).
Verona Pharma Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| VTYX | Ventyx Biosciences | $2.37 | $33.86 | 1328.69% | Buy |
| INZY | Inozyme Pharma | $2.94 | $16.00 | 444.22% | Buy |
| XFOR | X4 Pharmaceuticals | $0.74 | $3.67 | 395.95% | Buy |
| ABOS | Acumen Pharmaceuticals | $1.96 | $7.00 | 257.14% | Buy |
| TERN | Terns Pharmaceuticals | $6.80 | $18.67 | 174.56% | Buy |
| MREO | Mereo BioPharma Group | $3.40 | $8.00 | 135.29% | Buy |
| SNDX | Syndax Pharmaceuticals | $13.63 | $31.67 | 132.36% | Buy |
| VKTX | Viking Therapeutics | $46.70 | $97.80 | 109.42% | Buy |
| APLS | Apellis Pharmaceuticals | $34.53 | $70.80 | 105.04% | Buy |
| IDYA | IDEAYA Biosciences | $26.33 | $53.33 | 102.54% | Buy |
| AMLX | Amylyx Pharmaceuticals | $4.28 | $8.25 | 92.76% | Buy |
| DAWN | Day One Biopharmaceuticals | $12.64 | $24.00 | 89.87% | Buy |
| MLTX | MoonLake Immunotherapeutics | $56.30 | $100.00 | 77.62% | Buy |
| AKRO | Akero Therapeutics | $30.61 | $50.00 | 63.35% | Buy |
| PTGX | Protagonist Therapeutics | $40.69 | $57.33 | 40.89% | Buy |
| MDGL | Madrigal Pharmaceuticals | $306.08 | $315.75 | 3.16% | Buy |
| VRNA | Verona Pharma | $41.66 | $39.50 | -5.18% | Buy |